A carregar...
Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
BACKGROUND: Immune checkpoint inhibitors (ICIs) have made a paradigm shift in clinical oncology due to unprecedented long-term remissions. However, only a small proportion of patients respond to ICI therapy. It is, therefore, essential to understand the mechanisms driving therapy resistance and to d...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7957134/ https://ncbi.nlm.nih.gov/pubmed/33707313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001996 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|